Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine

通过靶向 MDSC 衍生的腺苷克服癌症免疫治疗的耐药性

• 批准号: 10093114
• 负责人: Kavitha Yaddanapudi
• 金额: $ 27.17万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10093114
• 关键词: 5' -Nucleotidase; Adenosine; Adopted; Advanced Malignant Neoplasm; Attenuated; CD8-Positive T-Lymphocytes; CD8B1 gene; CREB1 gene; Cancer Center; Cancer Model; Cancer Patient; Cattle; Cell physiology; Cell surface; Cells; Child; Clinical; Consumption; Critical Pathways; Cyclic AMP; Data; Dinoprostone; Disease; Enzymes; Epidermal Growth Factor Receptor; FDA approved; Frequencies; Generations; Goals; Homing; Human; Immune; Immune Cell Suppression; Immune checkpoint inhibitor; Immune system; Immunotherapeutic agent; Immunotherapy; Impairment; Implant; In Vitro; In complete remission; Inosine; Knock-out; Lung Neoplasms; Malignant Neoplasms; Malignant neoplasm of lung; Mediating; Mediator of activation protein; Molecular; Mus; Myeloid-derived suppressor cells; Non-Small-Cell Lung Carcinoma; Nonmetastatic; Nucleosides; Outcome; PD-1 inhibitors; Pathway interactions; Patients; Polyethylene Glycols; Prostaglandin Inhibition; Purine Nucleosides; Regulation; Resistance; STAT3 gene; Severe Combined Immunodeficiency; Signal Pathway; Signal Transduction; T-Cell Activation; T-Lymphocyte; Testing; Transgenic Model; Tumor Immunity; Tumor-Derived; adenosine deaminase; anti-CTLA4 antibodies; anti-PD-1; anti-PD1 antibodies; anti-PD1 therapy; cancer immunotherapy; clinically relevant; conditional knockout; effector T cell; enzyme replacement therapy; extracellular; improved; in vivo; inhibitor/antagonist; insight; monocyte; mouse model; neoplastic cell; novel; objective response rate; pembrolizumab; programmed cell death ligand 1; response; therapeutic target; therapy development; therapy resistant; transcription factor; tumor; tumor growth; tumor immunology; tumor microenvironment

Lung cancer is a prevalent disease and consumes many lives every year. Cancer immunotherapy using immune checkpoint inhibitors (ICIs; e.g. anti-PD-1, anti-CTLA-4 antibodies) has revolutionized the treatment of metastatic lung cancer, resulting in long-term complete responses for many patients. Nevertheless, there remains an urgent need for new strategies because not all patients respond to ICIs; moreover, resistance can occur in those that do. Myeloid-derived suppressor cells (MDSCs), in particular, monocytic MDSCs (MMDSCs) are potent immunosuppressive innate immune cells that actively inhibit CD8+ T cell tumor homing and activation. Since M-MDSC levels are elevated in multiple human cancers and correlate with decreased patient survival, we postulate that these cells contribute to anti-PD-1 resistance. The purine nucleoside, adenosine, is produced in copious amounts within the tumor microenvironment (TME), where it serves to suppress the immune system and promote tumor growth. There is evidence to suggest that overproduction of adenosine can mediate resistance to ICIs. Immune suppressive adenosine is produced via the enzymatic conversion of extracellular AMP by the cell surface enzyme, CD73 (ecto-5’-nucleotidase; AMP → adenosine). Our preliminary studies demonstrate that tumor cell-derived prostaglandin E2 (PGE2) maintains M-MDSC suppressive activity, in large part, by directly inducing cell surface CD73 expression via a novel PGE2→cAMP→CREB/STAT3 pathway leading to increased immune suppressive adenosine within the TME. The overall hypothesis of this proposal is that tumor cell-derived PGE2 dictates CD73 expression in M-MDSCs leading to substantial increases in adenosine-dependent inhibition of anti-tumor CD8+ T cell activation resulting, ultimately, in anti-PD-1 immunotherapeutic resistance A major goal of this proposal is to test the antitumor efficacy of a novel cancer immunotherapy involving systemic administration of adenosine deaminase (ADA)—an enzyme that irreversibly converts adenosine into inosine, a non-immunosuppresive nucleoside. A pegylated version of bovine ADA (PEG-ADA) is already FDA-approved for use as an enzyme replacement therapy in children with ADA-associated severe combined immunodeficiency (ADA-SCID). We hypothesize that depletion of adenosine-mediated T cell immune suppression by PEG-ADA sensitizes tumors to PD-1 inhibitor therapy and improves clinical outcomes for NSCLC patients. To fulfill the stated objectives, the following aims are proposed: 1) Delineate the signaling pathway and molecular mechanisms by which PGE2 induces CD73 expression in M-MDSCs; 2) Determine whether inhibition of the PGE2→cAMP→CREB/STAT3→CD73→adenosine pathway attenuates anti-PD-1 resistance in a mouse model of lung cancer; and 3) Validate PGE2 → CD73+ M-MDSC → adenosine mediated anti-PD-1 resistance pathway in lung cancer patients receiving pembrolizumab therapy. Our proposed study will provide important insights towards developing a safe and novel immunotherapy to attenuate ICI resistance in lung cancer patients.

肺癌是一种流行疾病，每年夺去许多人的生命。使用免疫检查点抑制剂（ICIs，如抗pd -1，抗ctla -4抗体）的癌症免疫治疗已经彻底改变了转移性肺癌的治疗，导致许多患者的长期完全缓解。尽管如此，仍然迫切需要新的策略，因为并非所有患者都对ici有反应；更重要的是，这样做的人可能会产生耐药性。髓源性抑制细胞（MDSCs），特别是单核细胞MDSCs （mmdsc）是一种有效的免疫抑制先天免疫细胞，可以有效地抑制CD8+ T细胞的肿瘤归巢和激活。由于M-MDSC水平在多种人类癌症中升高，并与患者生存率下降相关，我们假设这些细胞有助于抗pd -1耐药性。嘌呤核苷，腺苷，在肿瘤微环境（TME）中大量产生，在那里它抑制免疫系统并促进肿瘤生长。有证据表明腺苷的过量产生可以介导对ICIs的抵抗。免疫抑制腺苷是通过细胞表面酶CD73（外5′-核苷酸酶；AMP→腺苷）对细胞外AMP的酶转化产生的。我们的初步研究表明，肿瘤细胞源性前列腺素E2 （PGE2）维持M-MDSC抑制活性，在很大程度上是通过新的PGE2→cAMP→CREB/STAT3途径直接诱导细胞表面CD73表达，导致TME内免疫抑制腺苷增加。该提案的总体假设是，肿瘤细胞来源的PGE2决定了M-MDSCs中CD73的表达，导致抗肿瘤CD8+ T细胞活化的腺苷依赖性抑制显著增加，最终导致抗pd -1免疫治疗耐药性。该提案的主要目标是测试一种新型癌症免疫疗法的抗肿瘤功效，该疗法涉及全身给药腺苷脱氨酶（ADA）——一种将腺苷不可逆地转化为肌苷的酶。一种非免疫抑制核苷一种聚乙二醇化的牛ADA （PEG-ADA）已经被fda批准用于ADA相关的儿童严重联合免疫缺陷（ADA- scid）的酶替代疗法。我们假设，PEG-ADA消除腺苷介导的T细胞免疫抑制使肿瘤对PD-1抑制剂治疗敏感，并改善非小细胞肺癌患者的临床结果。为了实现上述目标，提出以下目标：1)描述PGE2诱导M-MDSCs中CD73表达的信号通路和分子机制；2)确定抑制PGE2→cAMP→CREB/STAT3→CD73→腺苷通路是否能减弱肺癌小鼠模型的抗pd -1耐药；3)验证PGE2→CD73+ M-MDSC→腺苷介导的抗pd -1耐药途径在接受派姆单抗治疗的肺癌患者中的作用。我们提出的研究将为开发一种安全和新颖的免疫疗法来减轻肺癌患者的ICI耐药性提供重要的见解。